鼠肝DNA甲基化酶的纯化及物理化学性质的研究

以Ｗｉｓｔａｒ大鼠肝为材料,确立了一个简便的纯化鼠肝ＤＮＡ甲基化酶的程序,包括：细胞的超声破碎、去内源核酸、硫酸铵盐析、磷酸纤维素亲和层析、ＤＥＡＥ－ＳｅｐｈａｄｅｘＡ－５０柱层析及ＳｅｐｈａｄｅｘＧ－１５０凝胶过滤。用不同浓度聚丙烯酰胺凝胶电泳和孔梯度凝胶电泳检测,纯化后的酶已达电泳均一,且酶的比活力提高１１２倍。以聚丙烯酰胺孔梯度凝胶电泳测得其天然酶的分子量为３６５ｋＤ,以ＳＤＳ－聚丙烯酰胺凝胶电泳测得该酶有两种亚基,大亚基为９５ｋＤ,小亚基为８５ｋＤ,推测该酶由两个大亚基和两个小亚基组成。     

Arg77和Glu80定点突变同时去除葡激酶中的T和B细胞抗原表位

【目的】对葡激酶的T和B细胞抗原表位重叠的关键氨基酸Arg77和Glu80进行定点突变以降低葡激酶的免疫原性。【方法】基于Arg77和Glu80的溶剂可及表面积设计葡激酶的突变体;突变体在大肠杆菌DH5α中进行表达。经过三步层析法纯化后,分析突变体的纤溶活性和免疫原性。【结果】免疫学实验提示,葡激酶导致Th2免疫反应;Glu80突变为丙氨酸和丝氨酸减少了溶剂可及表面积,同时去除了部分T和B细胞抗原表位;Arg77突变为天冬酰胺、谷氨酰胺和赖氨酸仅去除了部分T细胞抗原表位;6个组合突变体中,Sak(R77Q/E80A)和Sak(R77Q/E80S)有效去除了部分B和T细胞抗原表位,降低了葡激酶的免疫原性;Sak(R77Q/E80A)and Sak(R77Q/E80S)的纤溶活性和催化效率与r-Sak相当。     

Is it necessary for screening irregular antibodies of blood donors?

To explore the necessity of electronic crossmatching applied to irregular antibodies from blood donors, to ensure blood transfusion safety. Irregular antibody screening was performed on blood samples collected in the Dongguan Blood Center from Apr 17, 2014 to Dec 31, 2017. Primary screening was performed on the Sanquin automatic blood group analyzer by the microcolumn gel method (Sanquin). The positive samples were analyzed again using the salt medium method, polybrene method and micro-column gel method (Diana) for the second screening. If the second screening was positive, it was used to determine irregular antibody specificity (using panel cells) and any irregular antibody titer was detected. A total of 208,004 samples were detected, of which 316 were positive (316/208,004; 0.152%). Among them, 120 alloantibodies (120/135,139; 0.088%) were detected in male donors, which was much lower than in female donors (173/72,865; 0.237%) (P<0.01). A total of 16 kinds of known irregular antibodies and 40 cases of unknown antibody specificity were detected, with 119 cases of IgG type and 197 cases of IgM type, at the ratio of 1.65:1. In female donors, the frequencies of anti-D, anti-E, anti-M and anti-Le^a were significantly higher than in male donors (P<0.01). In married couples, the frequencies of anti-D and anti-E were significantly higher than those unmarried (P<0.05). In minority nationalities, the frequency of anti-M was significantly higher than in the Han nationality (P<0.05). In non-Guangdong donors, the frequencies of anti-D and anti-Le^a were significantly higher than in Guangdong donors. 87.02% of irregular antibody positive donors’ antibody titers were lower than “++”, which was deemed as no serious hazard for clinical transfusion. The study suggests that it is unnecessary to screen for irregular antibodies in blood donors. Male donors from Guangdong may not be required to undergo screening for irregular antibodies, and anti-D and anti-E only identification is also not required to be detected in female donors.     

The regulation of necroptosis by ubiquitylation

Necroptosis is a programmed necrosis that is mediated by receptor-interacting protein kinases RIPK1, RIPK3 and the mixed lineage kinase domain-like protein, MLKL. Necroptosis must be strictly regulated to maintain normal tissue homeostasis, and dysregulation of necroptosis leads to the development of various inflammatory, infectious, and degenerative diseases. Ubiquitylation is a widespread post-translational modification that is essential for balancing numerous physiological processes. Over the past decade, considerable progress has been made in the understanding of the role of ubiquitylation in regulating necroptosis. Here, we will discuss the regulatory functions of ubiquitylation in necroptosis signaling pathway. An enhanced understanding of the ubiquitylation enzymes and regulatory proteins in necroptotic signaling pathway will be exploited for the development of new therapeutic strategies for necroptosis-related diseases.

     

老年高血压合并2 型糖尿病患者血清同型半胱氨酸、血尿酸水平 变化及临床意义

目的：探讨老年高血压合并2 型糖尿病患者血清同型半胱氨酸（Homocysteine, Hcy）、血尿酸（Serum uric acid, SUA）水平变 化及其临床意义。方法：2012 年9 月至2013 年9 月期间,我院诊治的40 例单纯高血压和40 例高血压合并2 型糖尿病患者,分别 作为对照组和研究组,检测两组血清Hcy、SUA水平。结果：两组患者收缩压、舒张压比较无统计学差异（P>0.05）。研究组空腹血 糖、餐后2h 血糖、血清Hcy、SUA 均显著高于对照组（P<0.05）。研究组中血管并发症患者血清Hcy、SUA为（25.0± 5.0）umol/L 和 （390.0± 65.0）mmol/L显著高于无血管并发症患者（17.0± 4.0）umol/L 和（330.0± 55.0）mmol/L,血管并发症患者FBG、餐后2h 血 糖与无血管并发症患者比较无统计学差异（P>0.05）。结论：高血压合并2 型糖尿病患者血清Hcy、SUA异常升高,且存在慢性血 管并发症患者两者水平更高,血清Hcy、SUA是老年高血压合并2 型糖尿病的危险因素。     

第Ⅷ凝血因子基因内限制性片段长度多态性(RFLP)的研究及其在甲型血友病基因连锁分析中的应用

本文系统地研究了广东地区汉族人群中FⅧ:C基因内BclⅠ,XbaⅠ和BgⅡ位点RFLP的基因频率。多态性位点BclⅠ,XbaⅠ及BglⅠ的切点阳性率分别为63.5%、43.5%和100%。对Bcll和Xbal多态性切点连锁情况研究显示,19.5%的Bcll切点阳性纯合子为Xbal切点杂合子,证明联合应用此两位点RFLP可以把甲型血友病基因连锁分析的有效率提高到65.9%。用RFLP连锁分析对两例甲型血友病家系中的女性进行了致病基因携带者检测,对另一例家系进行了基因产前诊断。     

具有抗血小板聚集功能的新型葡激酶突变体的表达、纯化及性质

[目的]为解决溶栓后再栓塞问题,构建N-端含RGD(Arg-Gly-Asp)序列的葡激酶双功能突变体.研究突变体的表达和纯化,并进行性质分析.[方法]将突变后的葡激酶突变体序列连入pBV220质粒,转化大肠杆菌BL21进行表达.阳离子交换、凝胶过滤和阴离子交换三步层析法纯化表达产物,采用溶圈法对纯化产物进行生物学活性测定,并测定纯化产物对血小板聚集的抑制效应.[结果]PAGE扫描结果显示,葡激酶突变体蛋白在大肠杆菌BL21中的表达量约占菌体蛋白总量的40%～50%;三步层析纯化后,HPLC测定其纯度可达95%.酪蛋白凝胶板溶圈法测得其比活性分别为10.8×104和11.0×104HU/mg,与野生型葡激酶活性相当;且具有明显的抗血小板聚集活性,血小板聚集仪测定其血小板聚集抑制率分别为10.72%和19.71%,明显高于野生型葡激酶血小板聚集抑制率.本实验利用pBV220载体高效表达了葡激酶突变体基因,得到了高纯度、高活性的突变体蛋白,为葡激酶生产产业化和临床应用奠定了良好的基础.     

ADA-LacZ融合基因直接注射导入小鼠皮肤组织后的表达

将ADA－LacZ融合基因经直接注射导入小鼠皮肤组织,用注射点处的皮肤组织制作冰冻切片,经组织化学方法显示：此融合基因可在皮肤成纤维细胞中表达一种具有腺苷脱氨酶（ADA）和β-半乳糖昔酶（β-gal）双重酶活性的融合蛋白,这种直接将融合基因导入体内进行表达的方式．为在基因治疗和基因疫苗研究中探索一条新的简便可行的外源基因在体内表达的途径,提供了有益的实验依据。